COVID-19, caused by SARS-CoV-2, is characterised by a broad spectrum of symptom severity that requires varying amounts of care according to the different stages of the disease. Intervening at the onset of mild to moderate COVID-19 symptoms in the outpatient setting would provide the opportunity to prevent progression to a more severe illness and long-term complications. As early disease symptoms variably reflect an underlying excessive inflammatory response to the viral infection, the use of anti-inflammatory drugs, especially non-steroidal anti-inflammatory drugs (NSAIDs), in the initial outpatient stage of COVID-19 seems to be a valuable therapeutic strategy. A few observational studies have tested NSAIDs (especially relatively selective COX-2 inhibitors), often as part of multipharmacological protocols, for early outpatient treatment of COVID-19. The findings from these studies are promising and point to a crucial role of NSAIDs for the at-home management of people with initial COVID-19 symptoms.

由 SARS-CoV-2 引起的 COVID-19 具有广泛的症状严重程度，需要根据疾病的不同阶段进行不同程度的护理。在门诊环境中出现轻度至中度 COVID-19 症状时进行干预，将有机会防止进展为更严重的疾病和长期并发症。由于早期疾病症状可变地反映了对病毒感染的潜在过度炎症反应，因此在 COVID-19 的初始门诊阶段使用抗炎药，尤其是非甾体抗炎药 (NSAIDs) 似乎是一种有价值的方法治疗策略。一些观察性研究测试了非甾体抗炎药（尤其是相对选择性的 COX-2 抑制剂），通常作为多药理学方案的一部分，用于 COVID-19 的早期门诊治疗。这些研究的结果很有希望，并指出了非甾体抗炎药对于具有 COVID-19 初始症状的人的居家管理的关键作用。